CORE LABORATORIES N.V. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-04-26: Form 8-K; Period of report 2023-04-26; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
- 2023-04-04: Form 8-K; Period of report 2023-04-03; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2023-02-03: Form 8-K; Period of report 2023-02-02; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2023-02-01: Form 8-K; Period of report 2023-02-01; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-04-26 | 8-K | 2023-04-26 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On April 26, 2023, Core Laboratories N.V. issued a press release announcing its financial results for the first quarter of 2023. 7.01 On April 26, 2023, Core Laboratories N.V. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on May 8, 2023 and payable May 30, 2023. | clb-20230426.htm |
| 2023-04-04 | 8-K | 2023-04-03 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On March 29, 2023, Core Laboratories N.V. (“Core Lab” or the “Company”) held an Extraordinary General Meeting of Shareholders (the “Dutch Meeting”) to vote on the following matters: (1) a resolution (the “Transaction Proposal”) to approve a series of proposed and joint transactions (the “Transaction”), including (a) the merger (the “Merger”) of the Company with and into Core Laboratories Luxembourg S.A., a public limited liability company incorporated under the laws of Luxembourg (“Core Lab Luxembourg”), with Core Lab Luxembourg surviving, and (b) as soon as practicable following completion of the Merger, Core Lab Luxembourg migrating out of Luxembourg and domesticating as Core Laboratories Inc., a Delaware corporation (the “U.S. Redomestication”); and (2) a resolution (the “Articles of Amendment Proposal”) to amend the articles of association of the Company, as amended, (“Articles of Association”) to include a formula on the basis of which cash compensation to the Company’s shareholders who exercise their withdrawal right in connection with the Merger, as referred to in Section 2:333h (1) of the Dutch Civil Code, can be determined. | clb-20230403.htm |
| 2023-02-03 | 8-K | 2023-02-02 | 7.01 Regulation FD Disclosure | 7.01 On February 2, 2023, Core Laboratories N.V. (“Core Lab” or the “Company”) held its Q4 2022 earnings call and webcast (the "Webcast") and made the Webcast available on its website. | clb-20230202.htm |
| 2023-02-01 | 8-K | 2023-02-01 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On February 1, 2023, Core Laboratories N.V. issued a press release announcing its financial results for the fourth quarter of 2022 and year ending December 31, 2022. 7.01 On February 1, 2023, Core Laboratories N.V. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on February 13, 2023 and payable March 6, 2023. | clb-20230201.htm |
| 2023-01-17 | 8-K | 2023-01-17 | 8.01 Other Events | 8.01 On January 17, 2023, Core Laboratories N.V. (“Core Lab” or the “Company”) issued a news release announcing its intention to reorganize the Company’s corporate structure, which will include redomestication (the “Redomestication”) of the parent company from the Netherlands to the United States as Core Laboratories, Inc., a Delaware corporation (“Core Lab Delaware”). | d431525d8k.htm |